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Prediction of breast cancer 
molecular subtypes using 
radiomics signatures of synthetic 
mammography from digital breast 
tomosynthesis
Jinwoo Son1, Si Eun Lee1, Eun‑Kyung Kim1,2* & Sungwon Kim1,2*
We aimed to predict molecular subtypes of breast cancer using radiomics signatures extracted 
from synthetic mammography reconstructed from digital breast tomosynthesis (DBT). A total of 
365 patients with invasive breast cancer with three different molecular subtypes (luminal A + B, 
luminal; HER2‑positive, HER2; triple‑negative, TN) were assigned to the training set and temporally 
independent validation cohort. A total of 129 radiomics features were extracted from synthetic 
mammograms. The radiomics signature was built using the elastic‑net approach. Clinical features 
included patient age, lesion size and image features assessed by radiologists. In the validation cohort, 
the radiomics signature yielded an AUC of 0.838, 0.556, and 0.645 for the TN, HER2 and luminal 
subtypes, respectively. In a multivariate analysis, the radiomics signature was the only independent 
predictor of the molecular subtype. The combination of the radiomics signature and clinical features 
showed significantly higher AUC values than clinical features only for distinguishing the TN subtype. 
In conclusion, the radiomics signature showed high performance for distinguishing TN breast cancer. 
Radiomics signatures may serve as biomarkers for TN breast cancer and may help to determine the 
direction of treatment for these patients. 
Breast cancer is the most common cancer diagnosed in women, and the second leading cause of all cancer-related 
 deaths1. Early diagnosis of breast cancer and prediction of prognosis are the key goals of current clinical research.
Depending on the expression level of certain receptors, breast cancer can be divided into various subtypes, 
such as the luminal, human epidermal growth factor receptor 2 (HER2)-enriched, and triple-negative (TN) 
 subtype2,3. Among these, cancers of the TN subtype are more aggressive and difficult to  treat2,4,5. Therefore, they 
account for a large portion of breast cancer deaths that occur after  diagnosis6. Patients with TN breast cancer 
derive no benefit from endocrine therapy or trastuzumab, because they lack the appropriate targets for these 
drugs. On the other hand, TN breast cancer responds well to neoadjuvant chemotherapy and patients with good 
response show improved  prognosis7–9.
Several reports have found that findings on mammography, ultrasonography, or MRI are related to the 
molecular subtypes of breast  cancer10–12. Recently, several attempts have been made to predict these molecular 
subtypes through a radiomics approach. Radiomics refers to the transformation of image data into computer-
based, high-dimensional data. The resulting data reflect not only tissue characteristics but also gene  expression13. 
A few studies have shown that radiomics features obtained from magnetic resonance imaging (MRI) can be 
associated with the molecular subtypes of breast  cancer14–16.
Mammography is the primary modality for breast cancer diagnosis and can be performed in all patients while 
being highly accessible. Although MRI has advantages in tissue characterization, it is not yet a routine modality 
for all patients. Therefore, being able to predict molecular subtype by routinely performed mammography will 
be of clinical value, and several previous studies have shown the  possibilities17,18.
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The use of digital breast tomosynthesis (DBT) has increased, and adding DBT to digital mammography can 
increase the detection rate in breast cancer screening over digital mammography  alone19,20. However, using 
DBT with digital mammography for screening also increases the radiation  dose21. To overcome this, a method 
was developed to reconstruct synthetic mammography images from information acquired during a DBT data 
acquisition. More and more evidence indicates that synthetic mammography will eventually be able to replace 
digital  mammography22,23. Despite DBT becoming the primary modality in breast cancer diagnosis, there are 
problems such as higher reading  workload24 and inconsistency in mass segmentation, owing to the numerous 
slices of images. This limits the practicality and reproducibility in applying radiomics to DBT. Therefore, syn-
thetic mammography can be a good methodology for applying radiomics in clinical practice. However, to our 
knowledge, there is no research on using the radiomics approach on synthetic mammography from DBT for 
molecular subtyping.
The purpose of this study was to investigate whether radiomics features obtained from synthetic mammog-
raphy images reconstructed from DBT can distinguish different molecular subtypes of breast cancer.
Methods
Patient selection. This retrospective study was approved by the Institutional Review Board of Severance 
Hospital in Seoul, Korea. The requirement for informed consent was waived. All methods described in this 
manuscript were performed in accordance with the approved guidelines and regulations.
From December 2015 to September 2016, 691 patients who were pathologically diagnosed with invasive 
breast cancer and had preoperative DBT were enrolled in this study. Exclusion criteria were: (1) patients who 
received chemotherapy before DBT (n = 114), (2) patients who received surgical excision or vacuum-assisted 
biopsy (n = 41), (3) asymmetries that were only visible on a single view (n = 40), (4) diffuse infiltrative lesions 
involving the whole breast (n = 7), (5) lesions partially masked by a marker (n = 15), (6) lesions not fully included 
on synthetic mammography (n = 34), and (7) lesions not clearly delineated on synthetic mammography (n = 75).
Finally, 365 patients were included in this study. Because there are remarkable differences in incidence among 
molecular  subtypes25, the same number of patients was assigned to each group to avoid inappropriate feature 
selection due to class imbalance and to improve the performance of  classification26,27. Among the 294 patients 
who were diagnosed with breast cancer between December 2015 and July 2016, 50 consecutive patients were 
selected for each molecular subtype and assigned to the training set. The remaining cases were not included in the 
analysis. Accordingly, a total of 150 patients were finally included in the training set. For the validation cohort, 71 
temporally independent patients who were diagnosed with breast cancer between August 2016 and September 
2016 were included. The composition of the temporal validation was done according to the transparent reporting 
of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)  statement28. The validation 
cohort consisted of 50 patients of the luminal subtype, 9 of the HER2 subtype and 12 of the TN subtype (Fig. 1).
Pathologic examination. Pathologic diagnoses were based on postoperative tissue samples. A pathologic 
report of all breast cancers included the expression levels of the estrogen receptor (ER), progesterone receptor 
(PR) and HER2. Breast cancers were classified as “Luminal”, “HER2 (HER2-enriched)” or “TN (triple negative)” 
according to the ASCO/CAP  guidelines29. In our study, the luminal subtype included luminal A and luminal 
B. ER and/or PR positive breast cancers were classified as the luminal subtype. ER and PR negative with HER2 
positive breast cancers were classified as the HER2-enriched subtype. ER, PR, and HER2 negative breast cancers 
were classified as the TN subtype. For ER and PR, more than 1% of expression indicated positivity. For HER2, 
3 + indicated positivity. For equivocal expression of HER2 (2 +), fluorescence in situ hybridization (FISH) 2.0 or 
higher indicated positivity.
Image acquisition & tumor segmentation. DBT was performed using a mammography machine (Sele-
nia Dimensions System; Hologic,Marlborough, MA) with bilateral craniocaudal (CC) and mediolateral oblique 
(MLO) views. The X-ray tube rotated in a 15° arc with the breast compressed, and there were 15 projections for 
each view. After scanning, the projection data from the frames were combined to create 3D DBT images, and 2D 
synthetic mammography images were concurrently processed. In-plane resolution of synthetic mammography 
was 1890 × 2457 pixels for both MLO and CC views.
All synthetic mammography images underwent the following preprocessing steps before the radiomics analy-
sis. Each pixel was resampled to 0.1 × 0.1 mm in size, because this might affect radiomics features related to spatial 
information or tumor  texture30. The intensities of the pixels covering the breast were adjusted to have the same 
mean and standard deviation for all images.
The 2D region of interest (ROI) covering the tumor on synthetic mammography was manually segmented 
(Figs. 2 and 3) by one resident radiologist with 3 years of experience (reader 1) using the “MIPAV” software (https 
://mipav .cit.nih.gov). Then, the drawn ROIs were checked in detail and confirmed by a breast radiologist with 
25 years of subspecialty experience (reader 2). Disagreements about the ROI were resolved by a consensus-based 
discussion. Another breast radiologist with 1 year of subspecialty experience (reader 3) independently drew ROIs 
on images for 40 randomly selected patients from the training set to evaluate interobserver reproducibility. All 
readers were blinded to the molecular subtype or the pathologic report of the breast cancer.
Radiomics feature extraction & selection. Radiomics features were calculated based on segmented 
ROIs using an open source software, “PyRadiomics” (https ://pyrad iomic s.readt hedoc s.io, version 2.1.2)31. 
The categories of the radiomics features were as follows: (1) first order; 18 features, (2) GLCM; 22 features, (3) 
GLRLM; 16 features, and (4) GLSZM; 16 features. A full list of the features included in each category is described 
in the supplementary materials (Supplementary Table 1). Image filters such as Laplacian of Gaussian or wavelets 
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were not used in this study for a more intrinsic interpretation of the radiomics features. A total of 72 radiomics 
features were obtained for each view.
The elastic-net approach was used to select appropriate features and to build the radiomics model. Elastic-net 
is a logistic regression model which combines ridge regression and the least absolute shrinkage and selection 
operator (LASSO)32,33. Parameter tuning of the elastic-net was performed through ten-fold cross-validation. For 
the tuning coefficients λ and α, the criterion of minimum standard deviation and maximum AUC were applied, 
respectively.
Feature selection and modeling processes were done in the training set, using R software (version 3.5.1; http://
www.Rproj ect.org)34  and the “glmnet” package (version 2.0–16)33.
Figure 1.  Patient selection.
Figure 2.  Segmentation example 1. Example of tumor segmentation on synthetic mammography. The synthetic 
mediolateral oblique (A) and craniocaudal (B) views of a 58-year-old female diagnosed with the triple negative 
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Molecular subtype classification. We performed three binary classifications to predict molecular sub-
types. This was to obtain intuitive results while avoiding statistical  complexity17,35. In order to overcome the 
imbalanced number of lesions belonging to each category in the modeling process, we applied the synthetic 
minority oversampling technique (SMOTE) method. SMOTE is an oversampling method that is commonly 
used to improve random  oversampling36,37. After the modeling process, selected features were extracted and 
their linear combinations formed the radiomics signature of each lesion.
The modeling process was repeated for features obtained from the CC view only (CC model), features obtained 
from the MLO view only (MLO model), and concatenated features obtained from both views (CC + MLO model).
Clinical feature assessment. For all breast cancer lesions, two radiologists (reader 1 and reader 2) evalu-
ated the lesions on synthetic mammography images based on the Breast Imaging Reporting and Data System 
(BI-RADS)38. When the two radiologists made different observations, a consensus was reached for the final 
assessment. Clinical features in this study were patient age, lesion size and mammographic features based on 
BI-RADS.
Statistical analysis. Continuous values were compared with the Student’s t-test. All continuous variables 
were verified for normality by the Shapiro–Wilk test. Categorical variables were compared with Pearson’s Chi-
square test or Fisher’s exact test. Univariate and multivariate logistic regression analyses for clinical features 
were done to identify independent predictors of the molecular subtypes of breast cancer. A “combined model” 
was built by performing multivariate logistic regression that included both the radiomics signature and the 
independent variables from the multivariate analysis of clinical features. A two-sided P < 0.05 was considered to 
indicate a statistically significant difference. Classification performances were evaluated based on the receiver 
operating characteristic (ROC) curve and area under the curve (AUC) in the validation cohort. The two ROC 
curves were compared using Delong’s test. Consistency of the predicted and actual probabilities of a model was 
demonstrated by a calibration curve. To assess the clinical usefulness of a model, decision curve analysis was 
used to quantify the net benefit at different threshold probabilities in the validation cohort. The radiomics signa-
ture and the BI-RADS features were correlated using Pearson’s correlation coefficient. Interobserver reproduc-
ibility was assessed with the intraclass correlation coefficient (ICC). An ICC > 0.75 was considered to indicate 
good agreement.
Results
A total of 150 patients (TN = 50, HER2 = 50, Luminal = 50) were assigned to the training set and 71 patients 
(TN = 12, HER2 = 9, Luminal = 50) were assigned to the validation cohort (Table 1, Supplementary Table 2). All 
continuous variables showed normal distribution.
Radiomics features and prediction performance. Among all the radiomics features, 71 features in the 
MLO view and 58 features in the CC view showed good interobserver reproducibility (Supplementary Fig. 1). 
Finally, a total of 129 features were included in the analysis.
When concatenating (CC + MLO model) all features, 20 features were selected for TN vs non-TN, 18 for 
HER2 vs non-HER2, and 66 features for luminal vs non-luminal. A list of the selected features is included in the 
supplementary materials (Supplementary Table 3). When only features from the CC view were included (CC 
model), 6 features were selected for TN vs non-TN, 34 for HER2 vs non-HER2, and 43 features for luminal vs 
non-luminal. For the MLO view (MLO model), 17 features were selected for TN vs non-TN, 34 for HER2 vs 
non-HER2, and 42 features for luminal vs non-luminal. In the training set, the CC + MLO model yielded an 
AUC of 0.834 for TN, 0.842 for HER2, and 0.941 for the luminal subtype.
Figure 3.  Segmentation example 2. Example of tumor segmentation on synthetic mammography. The synthetic 
mediolateral oblique (A) and craniocaudal (B) views of a 47-year-old female diagnosed with the luminal 
subtype of breast cancer. The breast lesion appears as a spiculated mass with architectural distortion (arrow).
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In the validation cohort, the CC + MLO model yielded an AUC of 0.838 for TN, 0.556 for HER2, and 0.645 
for the luminal subtype. With the optimal cut-off value of the radiomics signature was applied in this model, the 
sensitivity and specificity of the models in the validation cohort were 83.3% and 79.7% for TN, 11.1% and 79.0% 
for HER2, 44.0% and 66.7% for the luminal subtype, respectively (Table 2).
When the AUCs of the CC + MLO, CC and MLO models were compared for the three binary classifications, 
no statistically significant differences were found (Table 3).
Comparison of prediction performance between the clinical and the radiomics models. We 
compared the predictive performance of the clinical model with the combined model. In the TN subtype, the 
univariate analysis of the clinical features showed that round shape, high density and architectural distortion 
were statistically significant features. In the multivariate analysis of the clinical model, round shape and high 
Table 1.  Characteristics of patients and lesions. TN triple-negative, LN lymph node. * Data are 













(N = 50) P value
Age* 54.08 ± 10.48 51.08 ± 11.80 0.388 52.70 ± 8.51 53.22 ± 12.85 0.877 55.66 ± 10.95 50.36 ± 12.58 0.027
Lesion size (mm)* 33.98 ± 17.45 29.47 ± 15.04 0.894 41.78 ± 19.55 28.33 ± 10.17 0.050 24.92 ± 14.41 28.68 ± 14.12 0.191
Menopausal status 0.841 0.861 0.104
Premenopausal 12 2 12 2 12 22
Postmenopausal 35 9 33 7 36 25
Not reported 3 1 5 0 2 3
Invasive cancer 1 1 0.617
Ductal 50 12 50 9 47 49
Lobular 0 0 0 0 3 1
LN status 0.990 0.431 0.837
Positive 11 2 11 3 20 18
Negative 39 10 39 6 30 32
Table 2.  Classification performance of the radiomics models in the validation cohort. TN triple-negative, AUC 
area under the receiver operating characteristic curve.
TN vs non-TN HER2 vs non-HER2 Luminal vs non-luminal
CC model
AUC 0.819 0.520 0.659
Accuracy 0.817 0.761 0.563
Sensitivity 0.750 0.222 0.440
Specificity 0.831 0.839 0.867
MLO model
AUC 0.791 0.645 0.627
Accuracy 0.718 0.747 0.521
Sensitivity 0.917 0.111 0.480
Specificity 0.678 0.839 0.619
CC + MLO model
AUC 0.838 0.556 0.645
Accuracy 0.803 0.704 0.507
Sensitivity 0.833 0.111 0.440
Specificity 0.797 0.790 0.667
Table 3.  Comparison of AUC (area under the receiver operating characteristic curve) values between the 
radiomics models (P value) with Delong’s test.
TN vs non-TN HER2 vs non-HER2 Luminal vs non-luminal
CC model vs MLO model 0.646 0.354 0.544
CC model vs CC + MLO model 0.526 0.694 0.742
MLO model vs CC + MLO model 0.250 0.171 0.647
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density were identified as independent factors for predicting the TN subtype (Table  4). The clinical model 
showed an AUC of 0.665 in the validation cohort (Table 5).
The multivariate analysis of independent clinical features with the radiomics signature revealed that the radi-
omics signature was the only statistically significant variable. The combined model yield an AUC value of 0.868 
in the validation cohort (Table 5). In the ROC analysis, the performance of the combined model was significantly 
higher than the clinical model (p = 0.0449, Fig. 4A).
The calibration curve (Fig. 4B) revealed that the combined model demonstrated better agreement between the 
predicted probability and the expected probability than the clinical model. The clinical decision curve (Fig. 4C) 
shows that in the threshold probability is 5% or more, the combined model demonstrated a larger net benefit 
than did the clinical model, indicating that the combined model had the best clinical utility for prediction of 
Table 4.  Univariate and multivariate logistic regression of the clinical model and combined model for the 
TN subtype of breast cancer. The 95% confidence intervals of the AUCs are shown in parentheses. TN triple-
negative, AUC area under the receiver operating characteristic curve.
Feature TN Non-TN
Univariate analysis Multivariate analysis With radiomics signature
P value Odds ratio P value Odds ratio P value Odds ratio
Age 54.08 ± 10.48 54.18 ± 9.870 0.954 0.999 (0.965, 1.034)
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TN subtype of breast cancer. The results of the univariate and multivariate analysis for the HER2 and luminal 
subtype are presented in the supplementary materials (Supplementary Table 4 and 5). The HER2 and luminal 
subtype did not differ when the performances of the clinical and the combined models were compared in the 
validation cohort (Table 5).
Correlation between the radiomics signature and BI‑RADS features. The correlations between 
the radiomics signature and the BI-RADS features for each molecular subtype of breast cancer are shown in 
Fig. 5 in the order of the correlation coefficient. For the TN subtype, round shape and high density showed a 
high positive correlation with the radiomics signature. Architectural distortion and segmental distribution of 
microcalcifications showed negative correlation. For the HER2 subtype, segmental distribution of microcalci-
fications, mass with microcalcifications and fine linear microcalcifications showed positive correlation with the 
radiomics signature, and gross features of the mass showed negative correlation. For the luminal subtype, fatty 
breast composition and spiculated margins showed positive correlation, and obscured margins and dense breast 
composition showed negative correlation.
Discussion
This study revealed that the TN subtype of breast cancer can be distinguished by radiomics analysis of synthetic 
mammography reconstructed from DBT. The radiomics model showed good performance for identifying the TN 
subtype in the temporally independent validation cohort. In addition, the combined model—a combination of 
the clinical model and radiomics signature—showed significantly higher performance compared to the clinical 
model only. This means that the radiomics signature has additive value to the clinical model, which consists of 
patient age, tumor size and qualitative imaging findings.
The combination of DBT and digital mammography has shown higher sensitivity for breast cancer than 
digital mammography alone in screening  settings19,20. However, patients who undergo mammography and DBT 
at the same time are exposed to higher radiation doses. Thus, efforts have been made to replace digital mam-
mography with synthetic mammography from  DBT21. Since synthetic mammography from DBT has shown 
comparable sensitivity with digital mammography, attempts have been made to use DBT alone as a screening 
modality in North  America22,23. As the role of DBT increases, more research has been actively conducted on 
applying radiomics to DBT.
A previous study demonstrated that radiomics could be used in DBT to discriminate cancerous breasts in 
patients with dense breasts and negative  mammography39. Another study showed that Ki-67 expression could 
Table 5.  AUC (area under the receiver operating characteristic curve) values of the clinical and combined 
model in the validation cohort. The 95% confidence intervals of the AUCs are shown in parentheses. TN triple-
negative.
Clinical model Combined model P value
TN 0.665 (0.504–0.826) 0.868 (0.730–1.000) 0.045
HER2 0.501 (0.230–0.771) 0.582 (0.361–0.804) 0.159
Luminal 0.680 (0.554–0.806) 0.677 (0.552–0.802) 0.952
Figure 4.  The ROC curve, calibration curve and decision curve of clinical and combined models for 
distinguishing TN vs. non-TN in the validation cohort. (A) ROC curve of the clinical model (blue dotted line) 
and combined model (red solid line). The AUC of the combined model was 0.868 and that of the clinical model 
was 0.665. The two ROC curves showed significant difference (p = 0.0449). (B) Calibration curves of clinical 
and combined models. The 45◦ black dotted line expresses the ideal prediction. The combined model is closer 
to the ideal prediction compared to the clinical model, especially at predicted probability of 0.3 or higher. (C) 
Decision curve of clinical and combined models. In the interval between 5 and 71% of threshold probability, the 
combined model adds more benefit than applying all or none of the patients, and clinical model.
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be predicted using radiomics in  DBT40. Although these were preliminary results, they suggest that the radiom-
ics methodology can be applied to DBT, similar to mammography. In this study, by using a radiomics analysis 
of synthetic mammography from DBT, we could discriminate the TN subtype with high performance. Patients 
with the TN subtype require different treatment approaches such as neoadjuvant chemotherapy for breast cancer 
than patients with other subtypes due to the absence of targeted agents and poorer  prognosis7. If we can obtain 
information about the TN subtype from the screening modality, DBT using radiomics will help clinicians estab-
lish appropriate treatment plans. In addition, radiologists can diagnose the TN subtypes with more confidence 
using the radiomics approach for DBT.
Previous studies using radiomics to predict the molecular subtypes of breast cancer were focused on  MRI14–16 
because of its high soft tissue contrast and visualization of tumor perfusion dynamics. One study reported an 
overall accuracy of 71.2% for subtyping using only the radiomics features of MRI, and 89.2% when combining 
these features with pathological  features14. Another study reported an AUC of 0.65–0.89 for each subtype when 
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using MRI data in TCGA/TCIA15. However, these studies only performed internal validation using the leave-
one-out method without an independent validation set. Due to differences in the biological characteristics and 
treatments of TN subtypes, some studies have attempted to distinguish the TN subtype from other subtypes. 
Radiomics analysis of both tumor and background parenchymal enhancement has increased the AUC from 
0.782 to 0.878 when predicting the TN  subtype16. Although MRI-based radiomics shows high performance, the 
importance of mammography-based radiomics remains valid, because MRI is an expensive modality and less 
available than mammography. Meanwhile, mammography is a first-line imaging modality for cancer screening 
and is applicable to almost all breast cancer patients. Another advantage of mammography is its higher spatial 
resolution and better ability to visualize microcalcifications compared to MRI. In addition, since mammography 
can be repeatedly performed during follow-up, it is expected that changes in the molecular subtype that occur 
frequently after neoadjuvant  chemotherapy41 will be identified by mammography-based radiomics analysis.
Recent pioneering studies suggested the possibility of predicting molecular subtypes by analyzing digital 
mammography with  radiomics17,18. Ma et al. showed that the TN, HER2, and luminal subtype can be dis-
tinguished with relatively high performance, and that the discrimination of the TN subtype shows the best 
 performance17. Zhang et al. also reported a high performance for distinguishing the TN subtype from non-TN 
subtypes using radiomics in digital  mammography18. However, these studies, like many other radiomics studies, 
are limited in that they did not evaluate an independent validation set. In addition, these studies were performed 
with digital mammography and it is not known whether the same performance can be guaranteed with synthetic 
mammography from DBT. The present study showed that a radiomics analysis of synthetic mammography could 
predict the TN subtype with high performance and validated this higher performance in an independent cohort. 
Our results showed similar performance levels with previous MRI radiomics  studies16. The relatively high per-
formance of DBT may be due to the higher resolution of the modality and uniformity of the imaging equipment 
compared to MRI. MRI has a variety of vendors, image sequences, and numerous image parameters, while DBT 
only has a limited number of devices commercially available and relatively few parameters, resulting in consistent 
images. In the study of radiomics, normalization is commonly used to overcome variations in imaging, but the 
uniformity of DBT equipment itself is still thought to be helpful. Future studies need to be conducted to confirm 
the multivendor reproducibility of DBT.
In our study, synthetic mammography was used instead of the original DBT image. This approach was chosen 
to consider actual clinical practice. It is possible to draw ROIs on synthetic mammography using the results of 
this study in clinical practice. However, it is impractical to draw ROIs on original DBT images. Also, there will 
be limitations on the reproducibility of ROI on the original DBT images. However, there is the possibility that 
some tomographic data may be lost on synthetic mammography. Therefore, future research needs to compare 
synthetic mammography and original DBT images by radiomics analysis.
Because radiomics extract features inherent to an image, correlations between radiomics features and qualita-
tive imaging findings are expected. Several studies have reported that some mammographic findings are associ-
ated with certain molecular subtypes of breast  cancer42,43. The TN subtype of breast cancer has been associated 
with round or oval mass and circumscribed  margin42 or oval shaped hyperdense  mass43. Consistent with these 
studies, in the present study, round shape and high density showed a high positive correlation with the radiomics 
signature for predicting the TN subtype. The HER2 subtype was reported to have indistinct margins with suspi-
cious  microcalcifications42 and the luminal subtype was reported to have spiculated margins and architectural 
 distortion42. Similar correlations were found between the radiomics signature and the imaging findings in this 
study. This means that the radiomics signature reflected mammographic findings associated with each molecular 
subtype. Conversely, this result means that new imaging findings can be found intuitively through morphological 
features represented by a combination of features revealed through radiomics analysis. For example, in this study, 
the radiomics signature suggesting the TN subtype showed positive correlation with obscured or microlobulated 
margins. Therefore, this needs to be verified in future studies that explore the correlation between mammographic 
finding and breast cancer subtype.
When trying to distinguish the HER2 and luminal subtype of breast cancer, the radiomics models failed to 
show sufficient performance in validation. In addition, there was no added value of combining the radiomics 
signature with the clinical model. When predicting the HER2 and luminal subtype of breast cancer, the radiomics 
model appeared to be overfitted to the training set and showed inferior performance in the validation cohort. 
This means that, unlike the TN type, radiomics failed to extract general characteristics suitable for the HER2 
and the luminal subtypes. A previous study reported that the phenotypes of the HER2 and luminal subtype had 
much in  common44. Microcalcifications and mammographically non-visible masses are well-known common 
morphologic characteristics of the two subtypes. Therefore, this result may not be a methodological limitation 
of radiomics, but may actually be due to a classification limitation based on the morphology difference between 
the HER2 and luminal subtype.
There are several limitations in this study. First, there were inherent limitations due to its retrospective study 
design. Second, a relatively large number of radiomics features were included in the final model. This makes it 
difficult to interpret the meaning of each individual radiomics feature. By showing the relationship between the 
radiomics signature and mammographic features, we verified that mammographic findings were reflected in the 
molecular subtype predicted by the radiomics analysis. Third, features with Laplacian of Gaussian or wavelet filter 
were not included. These features can characterize the high-dimensional image signal of the tumor. However, 
in this study, these features were excluded in consideration of the limited sample size. Future studies with larger 
sample sizes will need to include an analysis of these features. Fourth, the extraction of radiomics features was 
based on manually drawn ROIs. To overcome this, features with poor interobserver reproducibility were excluded 
from the analysis. Fifth, the sample size of the validation cohort is relatively small due to the temporal validation 
method adopted to split data. In future research, this can be overcome by using a larger sample size or by con-
sidering a different data composition method. Sixth, we adopted the binary classification method to classify the 
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three molecular subtypes. This is the method used by existing  studies17,35, and was intended to obtain intuitive 
results. In future research, we believe that it is necessary to perform multiclass classification using a different 
strategy such as softmax. Another limitation was that we only included lesions that were clearly delineated in 
synthetic mammography. Because the lesion contrast of synthetic mammography was limited compared to the 
original DBT images, a relatively large number of lesions were excluded from the analysis.
Conclusions
In conclusion, this study showed a significant relationship between radiomics signatures based on synthetic mam-
mography reconstructed from DBT images and molecular subtypes of breast cancer. The radiomics signature 
was able to distinguish the TN subtype of breast cancer with high accuracy. Since DBT is an imaging modality 
that can be performed in almost all patients, the radiomics signature can be used as a potential biomarker for 
the clinical diagnosis and treatment of breast cancer patients.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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